semaglutide depot / Mapi Pharma - LARVOL DELTA

Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus (clinicaltrials.gov) - P1/2 | N=24 | Recruiting | Sponsor: Mapi Pharma Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus (clinicaltrials.gov) - P1/2 | N=24 | Not yet recruiting | Sponsor: Mapi Pharma Ltd.

New P1/2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Semaglutide Depot, a Long-Acting Injection of Semaglutide Administered Once Every Four Weeks—Pharmacokinetic Modeling and Human-Based Allometric Scaling (ADA 2025) - "Based on the pre-clinical results Semaglutide Depot given once every 28 days in doses of 4 to 8 mg is expected to reach the target human PK profile while offering an improved safety profile. Phase I/II clinical study is planned to explore Semaglutide Depot PK, safety and efficacy in humans including these dose ranges."

PK/PD data • Metabolic Disorders